Clinical trials: Water
Healthy Volunteers
Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers
In accordance with International Conference on Harmonisation (ICH) E14 guidelines, this Phase I thorough QT (TQT) study will assess the arrhythmogenic potential of GFT505, by evaluating its effect on QT/QTc prolongation in…
- Trial name
- NCT02091310
- Testing
- GFT505, Moxifloxacin 400 mg
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy Volunteers
A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects
To evaluate the effect of oral pH on the pharmacokinetics (PK) of a single oromucosal dose of Sativex (four sprays containing 10.8 mg Δ9 tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD)) by comparing the PK profile of…
- Trial name
- NCT02240160
- Testing
- Sativex
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GW Pharmaceuticals Ltd
Nocturia
VA106483 Dose Response Study in Elderly Males
The main purpose of the study is to evaluate the way VA106483 enters and leaves the blood and tissues over time and how the drug acts on and in the body at various dose levels compared to placebo in the same volunteer.
- Trial name
- NCT00922740
- Testing
- VA106483
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Adenocarcinoma of Colon Recurrent
Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence
The decreased Estrogen Receptor beta (ERβ) expression in the non adenomatous mucosa of ApcMin/+ mice favours intestinal neoproliferation.
- Trial name
- CRC (NCT01402648)
- Testing
- Eviendep (CM&D Pharma Limited, UK), Maltodextrins
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- CM&D Pharma Limited
Overactive Bladder
Fesoterodine Flexible Dose Study
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence…
- Trial name
- NCT00536484
- Testing
- Fesoterodine
- Where
- 95 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer
Hyperkalemia
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other.
- Trial name
- PLATINUM (NCT04443608)
- Testing
- Patiromer Powder for Oral Suspension [Veltassa]
- Where
- 19 sites in United States
- Volunteers
- 115 people
- Sponsor
- Comprehensive Research Associates
Upper Gastrointestinal Bleeding
Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -Healthy Volunteers Study
The objective of the investigation is to evaluate the feasibility of detecting blood in healthy volunteers after ingestion of autologous blood mixed with water.
- Trial name
- NCT05631652
- Testing
- PillSense System
- Where
- Czechia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- EnteraSense Limited
Prostate Cancer
Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue
This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate.
- Trial name
- PERI III (NCT07561502)
- Testing
- Water Vapor Ablation
- Where
- Panama
- Volunteers
- 32 people
- Sponsor
- Francis Medical Inc.
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Acute Upper Respiratory Tract Infection
Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections
The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by immediate release (IR) guaifenesin (GGE) and do not match approved Mucinex labeling in the U.S.
- Trial name
- NCT01537081
- Testing
- Mucinex, Immediate-release Guaifenesin
- Where
- 43 sites in United States
- Volunteers
- 2,810 people
- Sponsor
- Reckitt Benckiser LLC
Healthy
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.
- Trial name
- NCT06816719
- Testing
- Treatment A: JW0106 1 tablet + C2101 1 tablet, Treatment B: JW0107 1 tablet
- Where
- South Korea
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Galactose Single Point (GSP), Residual Liver Function
Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)
The primary objective is to determine the oral galactose single point (OGSP) cutoff values to discriminate subjects with different hepatic function.
- Trial name
- NCT03457311
- Testing
- G.S.P. Oral Solution 400 mg/ml
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Richever Enterprise Co., Ltd.
Schizophrenia
A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule
The purpose of this study is to investigate the safety, tolerability and pharmacokinetic characteristics of JX11502MA capsule on healthy human, and to explore the relationship between the dose, pharmacokinetic parameters and…
- Trial name
- NCT05233657
- Testing
- JX11502MA
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Dyspareunia, Vaginal Dryness
Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action
This clinical investigation will look at the effectiveness and safety of two personal lubricants for the relief of intimate discomfort associated with vaginal dryness.
- Trial name
- NCT05644444
- Testing
- Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant), Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)
- Where
- Germany
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Spinal and Bulbar Muscular Atrophy
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
- Trial name
- NCT02024932
- Testing
- BVS857
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence, Healthy Japanese Subjects
Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects
This study will be an open-label, randomised, three-period, three-treatment, crossover study in healthy Japanese male and female of non-childbearing potential subjects, performed at a single study centre.
- Conditions
- Bioequivalence, Healthy Japanese Subjects, Pharmacokinetics
- Trial name
- NCT02436577
- Testing
- Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor IR tablet (90 mg) administered with 150 mL of water
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Toothache
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.
- Trial name
- NCT00720057
- Testing
- Naproxen Sodium ER (BAYH6689)
- Where
- 3 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bayer
Cardiovascular Diseases
Pharmacokinetic Behavior of Phenolic Acids Derived From Black Tea
This study is set up to determine pharmacokinetics of phenolic acids after a single oral dose to healthy males.
- Trial name
- NCT01533857
- Testing
- hot water, Black tea and phenolic acids
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Pancreatic Insufficiency, Cystic Fibrosis
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
- Conditions
- Pancreatic Insufficiency, Cystic Fibrosis, Digestive System Diseases, Lung Diseases
- Trial name
- NCT01710644
- Testing
- Burlulipase
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Nordmark Arzneimittel GmbH & Co. KG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.